BioSpace News Archive

Medication administration errors leading to death are common with anticoagulants and antibiotics in particular, according to a new study that analysed incidents reported in England and Wales.

he Ministry of Health and Prevention recently met with a Chinese delegation to discuss mutually beneficial cooperation in the use of technological innovations such as artificial intelligence (AI) in the health care sector.

An expert in the application of artificial intelligence in precision medicine, Christophe Béesau’s appointment will allow Metafora to step up its efforts in oncology and immunology

Dermavant Sciences today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.

First Approved Treatment for XLH in Canada that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease

Favorable safety and statistically significant efficacy demonstrated in a completed randomized, double-blind, placebo-controlled induction clinical trial based on clinical and endoscopic endpoints

AstraZeneca and its MedImmune division announced results from its Phase III EAGLE clinical trial. Imfinzi, in combination with tremelimumab, an anti-CTLA4 antibody, compared to standard-of-care (SoC) chemotherapy, failed to meet its primary endpoints in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progressed after platinum-based chemotherapy, regardless of the PD-L1 status of their cancer.

Late Thursday, Genentech said the U.S. Food and Drug Administration granted regulatory approval for a combination of Tecentriq and Avastin for treatment of some metastatic non-squamous non-small cell lung cancer (NSCLC) patients.

The long-awaited and massively hyped initial public offering of Moderna Therapeutics hit the market yesterday. The company sold approximately 26.3 million shares priced at $23 a share. This exceeded the revised goal of $600 million by about $4.3 million.

The government alleged Actelion provided money to a nonprofit to cover copay costs for Medicare drugs, a violation of the False Claims Act.